



NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL

**AD-HOC ANNOUNCEMENT
INSIDE INFORMATION ACCORDING TO ARTICLE 17 MAR**

**PAION AG RAISES EUR 5.2 MILLION IN
PRIVATE PLACEMENT**

- Financière Arbevel invests EUR 5.2 million

Aachen (Germany), 21 June 2018 – The Specialty Pharma Company PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange Prime Standard: PA8) announces that it will issue 2.6 million new shares in a private placement excluding shareholder subscription rights. All shares will be placed with Financière Arbevel, a French institutional investor, at a price of EUR 2.00 per share.

PAION will use the proceeds of the transaction to prepare the necessary work for the submission of the EU market approval dossier for remimazolam.

The capital increase consists of approximately 4% of PAION's current registered share capital. Following registration of the capital increase, the registered share capital will amount to EUR 63,720,046.00.

The new shares will be admitted to trading on the regulated market of the Frankfurt Stock Exchange.

End of inside information

###

About PAION

PAION AG is a publicly listed specialty pharmaceutical company developing and aiming to commercialize innovative drugs to be used in out-patient and hospital-based sedation, anesthesia and critical care services. PAION's lead compound is remimazolam, an intravenous, ultra-short-acting and controllable benzodiazepine sedative/anesthetic drug candidate for which PAION has completed the clinical development for use in procedural sedation in the U.S. Outside the U.S., PAION has so far focused on the development of remimazolam in the indication general anesthesia. A full clinical development program for general anesthesia was completed in Japan. In the EU, PAION is currently planning to continue the clinical development program by starting a Phase III trial in the second half of 2018. Development of remimazolam in the indication intensive care unit (ICU) sedation is also part of the longer-term life-cycle plan for remimazolam.

PAION is headquartered in Aachen (Germany) with an additional site in Cambridge (United Kingdom).

PAION's vision is to become an acknowledged “PAIONeer” in sedation and anesthesia.

Contact

Ralf Penner
Vice President Investor Relations/Public Relations
PAION AG
Martinstrasse 10-12
52062 Aachen – Germany
Phone: +49 241 4453-152
E-mail: r.penner@paion.com
www.paion.com

Disclaimer:

This release contains certain forward-looking statements concerning the future business of PAION AG. These forward-looking statements contained herein are based on the current expectations, estimates and projections of PAION AG's management as of the date of this release. They are subject to a number of assumptions and involve known and unknown risks, uncertainties and other factors. Should actual conditions differ from the Company's assumptions, actual results and actions may differ materially from any future results and developments expressed or implied by such forward-looking statements. Considering the risks, uncertainties and other factors involved, recipients should not rely unreasonably upon these forward-looking statements. PAION AG has no obligation to periodically update any such forward-looking statements to reflect future events or developments.

This publication constitutes neither an offer to sell nor a solicitation to buy any securities. The securities have already been sold.

This release may not be published, distributed or transmitted in the United States, Canada, Australia, Japan or any other jurisdiction in which the distribution or release would be unlawful. This release does not constitute an offer of securities for sale or a solicitation of an offer to purchase securities (the “**Shares**”) of PAION AG (the “**Company**”) in the United States, Germany or any other jurisdiction. The Shares may not be offered or sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended (the “**Securities Act**”). The Shares have not been, and will not be, registered under the Securities Act.